Salem Investment Counselors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $661K | Hold |
4,176
| – | – | 0.02% | 280 |
|
|
2026
Q1 | $533K | Hold |
4,176
| – | – | 0.02% | 279 |
|
|
2025
Q4 | $509K | Hold |
4,176
| – | – | 0.01% | 279 |
|
|
2025
Q3 | $418K | Hold |
4,176
| – | – | 0.01% | 301 |
|
|
2025
Q2 | $346K | Sell |
4,176
-425
| -9% | -$33.9K | 0.01% | 315 |
|
|
2025
Q1 | $373K | Hold |
4,601
| – | – | 0.01% | 285 |
|
|
2024
Q4 | $414K | Hold |
4,601
| – | – | 0.01% | 281 |
|
|
2024
Q3 | $455K | Sell |
4,601
-250
| -5% | -$24.6K | 0.01% | 281 |
|
|
2024
Q2 | $450K | Hold |
4,851
| – | – | 0.01% | 274 |
|
|
2024
Q1 | $460K | Hold |
4,851
| – | – | 0.02% | 271 |
|
|
2023
Q4 | $433K | Sell |
4,851
-6,000
| -55% | -$446K | 0.01% | 269 |
|
|
2023
Q3 | $792K | Sell |
10,851
-300
| -3% | -$24K | 0.03% | 194 |
|
|
2023
Q2 | $928K | Hold |
11,151
| – | – | 0.03% | 182 |
|
|
2023
Q1 | $850K | Hold |
11,151
| – | – | 0.03% | 190 |
|
|
2022
Q4 | $926K | Sell |
11,151
-225
| -2% | -$18.2K | 0.04% | 189 |
|
|
2022
Q3 | $902K | Sell |
11,376
-697
| -6% | -$58.8K | 0.04% | 180 |
|
|
2022
Q2 | $897K | Sell |
12,073
-489
| -4% | -$36.7K | 0.04% | 188 |
|
|
2022
Q1 | $1.13M | Sell |
12,562
-1,456
| -10% | -$134K | 0.04% | 180 |
|
|
2021
Q4 | $1.57M | Sell |
14,018
-487
| -3% | -$58.7K | 0.05% | 155 |
|
|
2021
Q3 | $1.82M | Hold |
14,505
| – | – | 0.1% | 143 |
|
|
2021
Q2 | $1.96M | Sell |
14,505
-500
| -3% | -$65.7K | 0.11% | 138 |
|
|
2021
Q1 | $2.04M | Buy |
15,005
+697
| +5% | +$104K | 0.12% | 126 |
|
|
2020
Q4 | $2.01M | Buy |
14,308
+2
| +0% | +$256 | 0.13% | 122 |
|
|
2020
Q3 | $1.59M | Buy |
14,306
+1,400
| +11% | +$157K | 0.12% | 120 |
|
|
2020
Q2 | $1.45M | Buy |
12,906
+56
| +0.4% | +$5.51K | 0.12% | 121 |
|
|
2020
Q1 | $995K | Hold |
12,850
| – | – | 0.1% | 134 |
|
|
2019
Q4 | $1.22M | Sell |
12,850
-105
| -0.8% | -$9.08K | 0.1% | 136 |
|
|
2019
Q3 | $988K | Sell |
12,955
-3,550
| -22% | -$295K | 0.09% | 140 |
|
|
2019
Q2 | $1.45M | Buy |
+16,505
| New | +$1.41M | 0.13% | 126 |
|
|
2017
Q2 | – | Sell |
-11,950
| Closed | -$829K | – | 787 |
|
|
2017
Q1 | $829K | Sell |
11,950
-1,200
| -9% | -$80.6K | 0.09% | 148 |
|
|
2016
Q4 | $778K | Sell |
13,150
-4,500
| -25% | -$278K | 0.09% | 143 |
|
|
2016
Q3 | $11.7K | Buy |
17,650
+175
| +1% | +$10.8K | 0.15% | 113 |
|
|
2016
Q2 | $945K | Sell |
17,475
-3,024
| -15% | -$166K | 0.11% | 137 |
|
|
2016
Q1 | $1.06M | Sell |
20,499
-5,100
| -20% | -$265K | 0.13% | 128 |
|
|
2015
Q4 | $1.79M | Hold |
25,599
| – | – | 0.23% | 97 |
|
|
2015
Q3 | $1.58M | Sell |
25,599
-8,946
| -26% | -$705K | 0.21% | 102 |
|
|
2015
Q2 | $2.9M | Buy |
34,545
+510
| +1% | +$39.7K | 0.35% | 76 |
|
|
2015
Q1 | $2.56M | Buy |
+34,035
| New | +$2.38M | 0.31% | 83 |
|
Other funds holding XBI
MSR
PR
SO
WT
AAS
WJWM
OPCM
WAM
Salem Investment Counselors's XBI Position: Q2 2026 in Review
Salem Investment Counselors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 4,176 shares worth $661K. The position accounts for 0.02% of the portfolio, ranked #280.
Salem Investment Counselors first reported a position in XBI in Q1 2015 and has held it in 38 quarters since. The position peaked at $2.9M in Q2 2015. 465 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Salem Investment Counselors held 4,176 shares of State Street SPDR S&P Biotech ETF worth $661K as of Q2 2026.
- Salem Investment Counselors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
- State Street SPDR S&P Biotech ETF made up 0.02% of Salem Investment Counselors's portfolio in Q2 2026, its #280 holding.
- Salem Investment Counselors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and has held it in 38 quarters since.
- Salem Investment Counselors's State Street SPDR S&P Biotech ETF position peaked at $2.9M in Q2 2015.
- 465 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.